Related by context. All words. (Click for frequent words.) 73 recurrent glioblastoma multiforme 73 malignant pleural mesothelioma 71 colorectal liver metastases 71 squamous cell lung cancer 71 prostate cancer PCa 71 relapsed MM 70 superficial bladder cancer 70 metastatic colorectal 70 HNSCC 70 metastatic bladder 70 prostate cancer CaP 70 epithelial tumors 69 preoperative chemotherapy 69 serous ovarian cancer 69 advanced adenomas 69 HER2 positive cancers 69 Adjuvant chemotherapy 69 renal tumors 69 nonsmall cell lung cancer 69 HER2 positive metastatic breast 69 pulmonary metastases 69 Hepatocellular Carcinoma HCC 69 anaplastic 69 grade gliomas 68 tumor histology 68 recurrent NSCLC 68 node metastases 68 colorectal adenoma 68 endocrine therapies 68 Basal cell 68 breast carcinoma 68 renal cell carcinomas 68 clinically localized prostate 68 grade cervical intraepithelial 68 pancreatic adenocarcinoma 68 metastatic gastric 68 seminoma 68 neuroendocrine cancers 68 Papillary 67 metastatic renal 67 GISTs 67 antiangiogenic therapy 67 BRCA deficient 67 taxane therapy 67 Glioblastoma Multiforme 67 HGPIN 67 CYT# potent vascular disrupting 67 completely resected 67 thyroid nodules 67 metastatic RCC 67 imatinib Gleevec 67 stage IIIA 67 stage IIIB 67 allogeneic HSCT 67 Surgical resection 67 locoregional recurrence 67 MGUS 67 histologic subtype 67 ZACTIMA 67 nonmetastatic 67 CIN3 67 NMIBC 67 locoregional 67 bone metastasis 67 metastatic malignant 67 nonmelanoma skin cancers 67 non squamous NSCLC 67 metastatic pancreatic 67 carcinoid 67 Gleevec resistant 67 invasive lobular 66 HER2 overexpression 66 Anthracycline 66 resectable 66 papillary renal cell carcinoma 66 prophylactic cranial irradiation 66 gefitinib Iressa 66 PCa 66 medically inoperable 66 cervical lesions 66 Glioblastoma Multiforme GBM 66 basal cell carcinoma BCC 66 prostate carcinoma 66 intravenous bisphosphonates 66 curative resection 66 advanced adenoma 66 haematologic 66 indolent lymphomas 66 HBeAg negative 66 Hurthle cell 66 metastatic lesions 66 KRAS mutations occur 66 ovarian carcinoma 66 chlamydial infection 66 squamous cell carcinoma SCC 66 Sentinel node biopsy 66 pancreatic carcinoma 66 lymphoma subtypes 66 Acute myeloid leukemia 66 thymic carcinoma 66 surgically resectable 66 tumor recurrence 66 lobular carcinoma 66 Temsirolimus 66 skeletal metastases 66 Radical prostatectomy 66 thymoma 66 BRAF inhibitor 66 histologies 66 recurrent prostate cancer 66 precursor lesions 66 Mitomycin C 66 adjuvant radiotherapy 66 neoadjuvant therapy 66 Bezielle 66 smoldering myeloma 66 Anaplastic 66 CIN2 + 66 cervical carcinoma 66 rituximab Rituxan 66 Anthracyclines 66 MMP inhibitors 66 follicular lymphomas 65 Crizotinib 65 PSADT 65 hematopoietic cancers 65 pituitary adenomas 65 malignant lymphoma 65 intravesical therapy 65 Squamous 65 cutaneous squamous cell carcinoma 65 sarcomatoid 65 metastatic malignant melanoma 65 PCNSL 65 MAGE A3 ASCI 65 EGFR inhibitors 65 tyrosine kinase inhibitors TKIs 65 erlotinib Tarceva ® 65 cytoreduction 65 hepatocellular carcinomas 65 basal cell cancers 65 invasive ductal breast cancer 65 concurrent chemoradiation 65 EGFR tyrosine kinase inhibitors 65 castrate resistant prostate cancer 65 mucinous 65 EGFR mutation positive 65 dasatinib Sprycel 65 micrometastases 65 Pemetrexed 65 receptor tyrosine kinase inhibitor 65 GnRH agonists 65 cediranib 65 biochemical recurrence 65 trastuzumab Herceptin ® 65 cinacalcet 65 baseline LDH 65 alkylating agent 65 ADPKD 65 atypical ductal hyperplasia 65 #F FDG PET 65 cisplatin chemotherapy 65 thalidomide Thalomid 65 INCB# [003] 65 mycophenolate mofetil 65 pediatric malignancies 65 invasive aspergillosis 65 squamous cell cancers 65 androgen ablation 65 motesanib 65 hormone receptor negative 65 follicular lymphoma FL 65 cisplatin resistant 65 recurrent GBM 65 carcinoid tumors 65 advanced metastatic renal 65 ximelagatran 65 metastatic kidney 65 castrate resistant 65 Waldenstrom macroglobulinemia 65 neoadjuvant chemotherapy 65 stage IIIb IV 65 myelofibrosis polycythemia vera 65 metastatic GIST 65 cytotoxic therapies 65 alkylating agents 65 Velcade bortezomib 65 lung metastases 65 CTEPH 65 heavily pretreated 65 operable breast cancer 65 peritoneal carcinomatosis 65 urothelial cancer 65 K ras mutations 65 osteosarcomas 65 heavily pretreated patients 65 alveolar rhabdomyosarcoma 65 galiximab 65 underwent resection 65 fallopian tube carcinoma 65 indolent NHL 65 precancerous condition 65 bladder tumors 65 mycosis fungoides 65 malignant growths 64 gemcitabine carboplatin 64 malignant ascites 64 Response Evaluation Criteria 64 recurrent metastatic 64 histological subtype 64 neoadjuvant treatment 64 thromboembolic disease 64 metastatic renal cell carcinoma 64 invasive ductal 64 malignant neoplasms 64 smoldering multiple myeloma 64 KRAS status 64 erlotinib Tarceva 64 refractory metastatic 64 lung pancreatic 64 thyroglobulin 64 MGd 64 seminomas 64 urothelial carcinoma 64 metastatic lymph nodes 64 adenomatous 64 Adenomas 64 ZOLINZA 64 secondary hyperparathyroidism 64 CP CPPS 64 Glioblastoma multiforme GBM 64 immunosuppressive therapies 64 chemoradiotherapy 64 unresectable tumors 64 surgical debulking 64 EGFR TKI 64 pheochromocytoma 64 acute leukemias 64 Chronic lymphocytic leukemia 64 squamous histology 64 lung cancer NSCLC 64 endometrial hyperplasia 64 BRAF mutations 64 postoperative chemotherapy 64 Cytoxan 64 invasive carcinoma 64 demonstrated antitumor activity 64 radiation therapy SBRT 64 Mitoxantrone 64 vinca alkaloids 64 bladder ovarian 64 hepatorenal syndrome 64 B Cell Lymphoma 64 stage IIIB IV 64 bladder cancers 64 metastatic renal cell 64 infliximab Remicade 64 imatinib therapy 64 T#I [002] 64 malignant neoplasm 64 leukemia AML 64 adenomatous polyps 64 RECIST Response Evaluation Criteria 64 GBMs 64 advanced metastatic prostate 64 polyp recurrence 64 taxane chemotherapy 64 invasive lobular carcinoma 64 CLL SLL 64 oral clodronate 64 cancer mCRC 64 advanced medullary thyroid 64 medullary thyroid cancer 64 Acute Myeloid Leukaemia AML 64 colorectal carcinoma 64 Squamous Cell 64 hormone receptor status 64 metastatic tumors 64 tumor subtypes 64 gastrointestinal stromal tumors 64 relapsed leukemia 64 EUS FNA 64 thoracoscopic lobectomy 64 deCODE ProstateCancer TM 64 untreated metastatic melanoma 64 fluorouracil 64 neuroendocrine carcinoma 64 dasatinib 64 Aflibercept 64 FluCAM arm 64 myelodysplastic syndrome MDS 64 hormone refractory 64 Adjuvant therapy 64 Metastatic 64 GIST tumors 64 colorectal lung 64 relapsed SCLC 64 adjuvant therapies 64 neoplasias 64 breast carcinomas 64 BEXXAR Therapeutic Regimen 64 bendamustine 64 Zevalin consolidation 64 distant metastasis 64 liver metastasis 64 T1c 64 ACTEMRA TM 64 bleomycin 64 myeloproliferative disorder 64 endometrial cancers 64 tumors GIST 64 hypervascular tumors 64 non metastatic osteosarcoma 64 ductal carcinomas 64 hepatic metastases 64 bronchogenic carcinoma 64 primary hyperparathyroidism 64 Ceplene/IL-2 64 Faslodex 64 AA Amyloidosis 64 dexrazoxane 64 metachronous 64 leukemia multiple myeloma 64 follicular thyroid cancer 64 intensive statin therapy 64 antibody MAb 63 paclitaxel cisplatin 63 glioblastoma multiforme GBM 63 HIV HCV coinfected 63 chemotherapeutic regimens 63 pleural mesothelioma 63 Zolinza 63 mRCC 63 neuroblastoma tumors 63 Radiofrequency ablation 63 epithelial ovarian cancer 63 Epidermal Growth Factor Receptor 63 cutaneous melanoma 63 Medullary thyroid cancer 63 stratifying patients 63 pancreatic neuroendocrine tumors 63 Polycythemia vera 63 recurrent glioblastoma 63 hyperacute 63 corticosteroid therapy 63 malignant lesions 63 Chronic Myelogenous Leukemia CML 63 transrectal ultrasound guided 63 hormonal therapies 63 curability 63 ixabepilone 63 colorectal neoplasms 63 testicular cancers 63 severe exacerbations 63 EGFR mutations 63 refractory prostate cancer 63 percutaneous biopsy 63 FUSILEV enhances 63 chemoradiation 63 brain tumor glioblastoma multiforme 63 Vidofludimus 63 HER2 expressing 63 Gleevec imatinib 63 HER2 positive breast 63 malignant pancreatic 63 metastatic lung cancer 63 Renal Cell Carcinoma RCC 63 pancreatic lung 63 malignancies 63 basal cell nevus syndrome 63 coinfected patients 63 HER2 expression 63 glomerular filtration 63 colorectal cancer liver metastases 63 lung tumors 63 neuroendocrine tumors 63 metastatic neuroendocrine tumors 63 underwent surgical resection 63 IV bisphosphonates 63 Acute Myelogenous Leukemia 63 ovarian breast 63 adverse cytogenetics 63 gastrointestinal stromal tumors GISTs 63 Metastatic colorectal cancer 63 precancers 63 endometrial carcinoma 63 pancreatic islet cell 63 unresectable 63 mesotheliomas 63 follicular lymphoma 63 tamoxifen Nolvadex ® 63 gastrointestinal stromal tumor GIST 63 Enzastaurin 63 acne vulgaris 63 Rectal cancer 63 acute promyelocytic leukemia 63 paclitaxel Taxol 63 gastric adenocarcinoma 63 curative therapy 63 clinically detectable 63 refractory colorectal cancer 63 Alessandro Riva 63 lymph node metastases 63 cervical lymph nodes 63 radical prostatectomy RP 63 interferon beta therapy 63 Malignant mesothelioma 63 Doxil ® 63 neovascular diseases 63 PSMA ADC 63 Pertuzumab 63 metastatic liver 63 anthracycline chemotherapy 63 subependymal giant cell 63 antitumor effect 63 neoadjuvant radiation 63 Vandetanib 63 Hematologic 63 liver metastases 63 peritoneal cancer 63 LHRH agonists 63 anthracycline taxane 63 antiproliferative effects 63 localized prostate 63 KRAS mutation 63 oligodendrogliomas 63 doxorubicin Adriamycin 63 relapsing remitting MS RRMS 63 ovarian pancreatic 63 Retreatment 63 recurrent glioblastoma multiforme GBM 63 ductal breast cancer 63 colorectal polyp 63 nonalcoholic steatohepatitis NASH 63 haematological cancers 63 p# biomarker 63 Cholangiocarcinoma 63 sorafenib Nexavar 63 papillary carcinoma 63 atypical hyperplasia 63 TTR amyloidosis 63 hA# 63 thyroid carcinoma 63 fibrate drugs 63 lymphocytosis 63 anti angiogenic drugs 63 immunohistochemical staining 63 prostate carcinomas 63 IGF IR 63 urine cytology 63 Pancreatic neuroendocrine tumors 63 gastrointestinal stromal tumors GIST 63 colorectal carcinomas 63 radiolabeled TM# 63 pCR 63 perioperatively 63 YONDELIS 63 adriamycin 63 cytoreductive surgery 63 aromatase inhibitors AIs 63 pancreatic prostate 63 estramustine 63 nodal metastasis 63 NSTE ACS 63 EndoTAGTM 1 63 refractory ovarian cancer 63 lymphomas leukemias 63 BRCA mutation carriers 63 renal carcinoma 63 Androgen deprivation therapy 63 Xelox 63 Neoadjuvant 63 PARP inhibition 63 figitumumab 63 elevated LDH 63 Tavocept 63 paricalcitol 63 Bacillus Calmette Guerin BCG 63 low expressors 63 Endometrial 63 prognostic indicator 63 conventional DMARDs 63 mTOR inhibitors 63 undergo prostate biopsy 63 paragangliomas 63 ovarian endometrial 63 Leukemias 62 specific antigen PSA 62 MDS AML 62 hormone deprivation 62 ErbB2 positive 62 Darinaparsin 62 Brain metastases 62 sentinel lymph node biopsy 62 Myelodysplastic Syndrome 62 acute myeloid 62 benign nodules 62 docetaxel Taxotere ® 62 FDG PET 62 squamous cell 62 non squamous 62 pertuzumab 62 mutated BRAF gene 62 intraperitoneal chemotherapy 62 Dasatinib 62 vWD 62 diabetic kidney 62 Telintra 62 #.#ng/ml 62 Oncotype 62 CBLC# 62 refractory Hodgkin 62 distant metastases 62 BCG refractory 62 leukemias lymphomas 62 Hodgkin lymphoma HL 62 diabetes mellitus DM 62 anti angiogenic agents 62 vandetanib 62 Naive Patients 62 transarterial 62 metastatic prostate cancer 62 fibroadenomas 62 contralateral breast 62 FOLFOX6 62 papillary 62 olaparib 62 Crohn disease CD 62 radiation chemoradiation 62 unresectable stage 62 Certolizumab pegol 62 cilengitide 62 oral Hycamtin 62 axillary dissection 62 asymptomatic carotid stenosis 62 Vidaza azacitidine 62 trans retinoic acid 62 vismodegib 62 serum PSA 62 prognostic variables 62 somatostatin analogues 62 chemotherapeutic agent 62 anti angiogenic therapy 62 kidney urologic 62 idarubicin 62 epithelioid 62 raloxifene Evista 62 non squamous histology 62 Fludarabine 62 Alemtuzumab 62 biliary tract cancer 62 HER2 amplification 62 esophageal gastric 62 lobular cancer 62 Glioblastoma multiforme 62 colorectal cancer CRC 62 interferon ribavirin 62 ovarian suppression 62 cytotoxic therapy 62 subclinical disease 62 clinicopathological 62 Erlotinib 62 Peginterferon alfa 2b 62 immunosuppressive regimen 62 Neulasta ® 62 Fluorouracil 62 mutated KRAS gene 62 undergoing radical prostatectomy 62 allogeneic bone marrow 62 therapeutic regimens 62 iniparib BSI 62 TNF blocker therapy 62 macroalbuminuria 62 glioblastoma tumors 62 FDG uptake 62 radiofrequency ablation RFA 62 Chronic pancreatitis 62 pT2 62 pegylated liposomal doxorubicin 62 esophagogastric junction 62 lymphomas 62 squamous cell cancer 62 paclitaxel Taxol R 62 Metastatic breast cancer 62 temsirolimus 62 JAK inhibitors 62 irinotecan chemotherapy 62 chemotherapy regimens 62 pre malignant lesions 62 inflammatory acne 62 BRAF V# mutation 62 elevated CRP 62 antiandrogens 62 alemtuzumab treated 62 Fludara ® 62 Basal Cell 62 LV dysfunction 62 myelomas 62 leiomyomas 62 parathyroid carcinoma 62 TTF Therapy 62 moderately emetogenic 62 androgen independent 62 pT3 62 Stage IIIb 62 calcineurin inhibitors 62 AGILECT R 62 Squamous Cell Carcinoma 62 vinca alkaloid 62 thrombotic complications 62 EGFR tyrosine kinase inhibitor 62 relapsed ovarian cancer 62 doublet chemotherapy 62 psoriatic arthritis PsA 62 AMN# [001] 62 bevacizumab Avastin ® 62 castration resistant prostate cancer 62 papillary thyroid carcinoma 62 cranial radiation 62 PROLARIS 62 dopaminergic therapy 62 BENICAR HCT 62 somatostatin analogs 62 MYCN amplification 62 histologically confirmed 62 BRAF V#E mutation 62 Gefitinib 62 multiple myeloma MM 62 curable cancers 62 androgen deprivation 62 HER2 negative 62 premalignant 62 taxane refractory 62 Subgroup analysis 62 chemo resistant 62 biochemical relapse 62 Squamous cell 62 FOLFOX4 62 basal cell skin 62 epithelial ovarian 62 alefacept 62 resistant hormone refractory 62 multimodality therapy 62 external beam radiotherapy 62 Glioma 62 antimetabolite 62 histopathologic examination 62 malignant polyps 62 ASCUS 62 benign proliferative breast 62 nasopharyngeal carcinoma 62 soft tissue sarcomas 62 Mantle Cell Lymphoma 62 flutamide 62 Vectibix monotherapy 62 myeloproliferative diseases 62 estrogen receptor negative 62 prostate cancer CRPC 62 panitumumab Vectibix 62 Subgroup analyzes 62 debulking surgery 62 nonseminoma 62 cabazitaxel 62 antiangiogenic agents 62 ccRCC 62 nonmelanoma 62 chemoresistant 62 Hormone Refractory Prostate Cancer 62 metastatic melanomas 62 antithrombotic agents 62 indolent lymphoma 62 CALGB # [001] 62 leukemia ALL 62 HCV infections 62 precancerous cervical lesions 62 paclitaxel Taxol ® 62 Platinol ® cisplatin 62 prednisone prednisolone 62 IDH1 mutation 62 ductal cancer 62 hepatocellular cancer 62 hematological malignancy 62 lenalidomide Revlimid R 62 KRAS wild 62 anthracycline containing 62 aminotransferases 62 CTAP# Capsules 62 situ CIS 62 taxane resistant 62 mycophenolate mofetil MMF 62 follicular Non Hodgkin 62 relapsing MS 62 Teriflunomide 62 DFMO 62 hypereosinophilic syndrome 62 radiochemotherapy 62 SLNB 62 cT3 prostate cancer 62 metastatic basal cell 62 alvespimycin 62 Estrogen Receptor 62 chlorambucil 62 imatinib Gleevec ® 62 Prognostic factors 62 Degarelix 62 panobinostat 62 cell carcinoma 61 catheter angiography 61 Candida infection 61 immunosuppressive regimens 61 breast cancer subtypes 61 cytogenetic responses 61 KRAS oncogene 61 invasive candidiasis 61 malignant lymphomas 61 leukotriene receptor antagonist 61 cardiotoxic 61 benign neoplasms 61 candidemia 61 NovoTTF 61 chemoradiation therapy 61 situ LCIS 61 BRAF mutation 61 lung nodules 61 trastuzumab DM1 61 malignant pheochromocytoma 61 CIN3 + 61 dexpramipexole 61 gastrointestinal stromal tumor 61 antithrombotic therapy 61 Trastuzumab 61 dasatinib Sprycel ® 61 VFEND 61 intestinal polyps 61 Stage IIB 61 HER2 positive tumors 61 aflibercept VEGF Trap 61 breast pancreatic 61 ependymoma 61 precancer 61 Shark cartilage 61 FDG PET imaging 61 Deforolimus 61 grade glioma 61 Gliadel Wafer 61 prognostically 61 cytotoxic chemotherapy 61 idraparinux 61 ovarian lung 61 CIMZIA ™ 61 lumiliximab 61 adenocarcinomas 61 VaD 61 AVASTIN 61 cytoreductive nephrectomy 61 localized renal 61 premalignant lesions 61 Bisphosphonate 61 pheochromocytomas 61 TNF antagonist 61 gallium nitrate 61 recurrent bladder 61 surrogate endpoint 61 Intravenous immunoglobulin 61 Her2 positive 61 nonmetastatic prostate cancer 61 induce remission 61 diagnosed glioblastoma multiforme 61 Cardiotoxicity 61 Acute myelogenous leukemia 61 mutated KRAS 61 Motesanib 61 placebo dexamethasone 61 metastatic ovarian cancer 61 small lymphocytic lymphoma 61 grade serous ovarian 61 refractory NSCLC 61 GnRH agonist 61 samalizumab 61 thyrotoxicosis 61 cetuximab Erbitux 61 acute GVHD 61 mCRC patients 61 biologic therapy 61 B7 H3 61 Carcinoma 61 antimetabolites 61 obstructive coronary 61 basal cell carcinomas 61 Imatinib 61 gefitinib 61 anaplastic thyroid carcinoma 61 pelvic malignancies 61 Tyrosine Kinase Inhibitors 61 neoadjuvant 61 efaproxiral 61 myeloid leukemia 61 castration resistant hormone refractory 61 NSCLC 61 caspofungin 61 leiomyosarcoma 61 chemopreventive agent 61 SUVmax 61 Relapsing remitting MS 61 adjuvant radiation 61 lymph node dissection 61 Gorlin syndrome 61 pulmonary metastasis 61 myelofibrosis MF 61 sentinel nodes 61 nasopharyngeal cancer 61 refractory indolent non 61 Belldegrun 61 colorectal adenocarcinoma 61 cholangiocarcinoma 61 recurrent ovarian cancer 61 Sorafenib 61 chemotherapy cisplatin 61 Glioblastoma 61 Toxicities 61 Metastatic Prostate Cancer 61 recurrent colorectal cancer 61 transthyretin amyloidosis 61 mg/m2 dose 61 Chronic Lymphocytic Leukemia CLL 61 Synovial sarcoma 61 visilizumab 61 myelodysplastic myeloproliferative diseases 61 gastrointestinal cancers 61 TroVax ® 61 OHR/AVR# 61 EGFR mutation 61 flavopiridol 61 tigecycline 61 IV NSCLC 61 Related Anemia 61 Malignant pleural mesothelioma 61 embryonal rhabdomyosarcoma 61 prostate adenocarcinoma 61 pharmacologic stress 61 pelvic lymphadenectomy 61 Riluzole 61 Amrubicin 61 mapatumumab 61 antihypertensive therapy 61 antigen PSA 61 anthracyclines taxanes 61 abacavir Ziagen 61 antiangiogenic drugs 61 squamous 61 PROCRIT ® 61 dexamethasone Decadron 61 ZACTIMA TM ZD# 61 vestibular schwannomas 61 previously untreated follicular 61 liver resection 61 Aplidin 61 intestinal metaplasia 61 assessing T DM1 61 Venous thromboembolism 61 Follicular Lymphoma 61 micrometastasis 61 pulmonary hypertension PH 61 allogeneic stem cell 61 preoperative staging 61 enzastaurin 61 chronic periodontitis 61 Cristofanilli 61 PCA3 scores 61 oesophageal adenocarcinoma 61 hematological disorders 61 adalimumab Humira 61 cutaneous T 61 castration resistant 61 Myelodysplastic Syndrome MDS 61 LHRH analogues 61 hormone LHRH agonist 61 Folfox 61 carcinoid tumor 61 lupus nephritis 61 grade cervical dysplasia 61 Afatinib 61 urinary bladder cancer 61 anterior uveitis 61 EGFr 61 angiogenesis inhibition 61 colorectal tumors 61 proteasome inhibitor 61 relapsed ALL 61 chemotherapy docetaxel 61 ALA PDT 61 tumors 61 BRAF gene 61 liposomal amphotericin B 61 minimally symptomatic 61 carotid plaques 61 intra arterial chemotherapy 61 factor TNF 61 mertansine 61 standard chemotherapy regimen 61 non resectable metastatic 61 undergone radical prostatectomy 61 HER2 + 61 recurrent VTE 61 eribulin mesylate 61 acute promyelocytic leukemia APL 61 aspirin clopidogrel 61 Immunohistochemical staining 61 fulvestrant 61 familial amyloidotic polyneuropathy FAP 61 ERBB2 61 prognostic indicators 61 anastrazole 61 Virulizin ® 61 lenalidomide dexamethasone 61 pilocytic astrocytomas 61 inhibit EGFR 61 commercialize deforolimus 61 proliferative diabetic retinopathy 61 MALT lymphoma 61 hypertrophic scars 61 paroxysmal AF 61 squamous non 61 Non Hodgkins lymphoma 61 receiving highly emetogenic 61 diabetic gastroparesis 61 Hematologic toxicity 61 lung metastasis 61 metastatic castration resistant 61 immune modulating 61 bladder carcinoma 61 MabThera Rituxan 61 antiangiogenesis 61 hepatocellular carcinoma liver 61 carbohydrate polymers 61 riociguat 61 neoplasm 61 Taxol ® 61 metastatic HER2 negative 61 radiotherapy RT 61 Gastrointestinal Stromal Tumors 61 Vicinium TM 61 β blockers 61 dosage regimens 61 extracranial 61 anaplastic astrocytoma 61 Hormonal therapy 61 total thyroidectomy 61 FOLFIRI alone 61 HRPC 61 direct thrombin inhibitors 61 Bleomycin 61 axillary nodes 61 ALK inhibitors 61 Cabazitaxel 61 PKC# 61 choroidal neovascularization 61 vulvar intraepithelial neoplasia 61 diagnose Alzheimer disease 61 prostate cancers 61 intraperitoneal therapy 61 selective modulator 61 LHRH agonist 61 Eculizumab 61 colorectal neoplasia 61 immunomodulatory therapy 61 FDG-PET/CT 61 latent celiac disease 61 mitoxantrone 61 beta blocker therapy 61 biliary stones 61 LHRH receptor positive 61 axillary lymph nodes 61 bortezomib Velcade 61 Antitumor Activity 61 Radioimmunotherapy 61 Neuvenge 61 platinum refractory 61 molecular subtypes 61 meningiomas 61 glioma tumors 61 Hydroxyurea 60 Ribavirin causes 60 radioiodine therapy 60 Bayer HealthCare Onyx Pharmaceuticals 60 testicular germ cell 60 leukaemias 60 pancreatic NET 60 doxorubicin cyclophosphamide 60 mitoxantrone plus 60 NATRECOR R 60 polycythemia vera PV 60 F FDG PET 60 malignant brain 60 anti leukemic 60 bortezomib refractory 60 poor metabolizers 60 decitabine 60 ß blockers